Jean-Pierre Ayoub

2.8k total citations · 1 hit paper
35 papers, 1.8k citations indexed

About

Jean-Pierre Ayoub is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean-Pierre Ayoub has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Jean-Pierre Ayoub's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Jean-Pierre Ayoub is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). Jean-Pierre Ayoub collaborates with scholars based in Canada, United States and Australia. Jean-Pierre Ayoub's co-authors include Guadalupe Cervantes, Svetislava J. Vukelja, Guy van Hazel, Vladimir Moiseyenko, L. Mauriac, David Miles, Joyce O’Shaughnessy, Robert Leonard, Wing‐Yiu Lui and Shailendra Verma and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Jean-Pierre Ayoub

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

2002 855 citations Joyce O’Shaughnessy, David Miles et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean-Pierre Ayoub Canada	14	1.3k	566	486	244	189	35	1.8k
А. Н. Махсон Russia	15	1.2k 1.0×	563 1.0×	397 0.8×	310 1.3×	110 0.6×	23	1.7k
Pavlos Papakostas Greece	26	1.5k 1.2×	841 1.5×	315 0.6×	439 1.8×	182 1.0×	104	2.2k
Naoki Kanomata Japan	22	840 0.7×	528 0.9×	337 0.7×	549 2.3×	246 1.3×	104	1.7k
Catharina Wenzel Austria	22	979 0.8×	376 0.7×	403 0.8×	221 0.9×	216 1.1×	48	1.4k
Remedios Penetrante United States	19	596 0.5×	498 0.9×	397 0.8×	442 1.8×	197 1.0×	35	1.5k
P Soulié France	25	1.7k 1.3×	761 1.3×	394 0.8×	369 1.5×	103 0.5×	118	2.3k
José Pablo Leone United States	21	716 0.6×	551 1.0×	365 0.8×	204 0.8×	101 0.5×	88	1.3k
J. Albanell Spain	7	797 0.6×	341 0.6×	213 0.4×	240 1.0×	68 0.4×	13	1.2k
Anna Kalogera‐Fountzila Greece	23	814 0.6×	460 0.8×	255 0.5×	196 0.8×	132 0.7×	68	1.5k
Ioannis Boukovinas Greece	24	1.4k 1.1×	626 1.1×	338 0.7×	315 1.3×	115 0.6×	84	1.8k

Countries citing papers authored by Jean-Pierre Ayoub

Since Specialization

Citations

This map shows the geographic impact of Jean-Pierre Ayoub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Pierre Ayoub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Pierre Ayoub more than expected).

Fields of papers citing papers by Jean-Pierre Ayoub

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Pierre Ayoub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Pierre Ayoub. The network helps show where Jean-Pierre Ayoub may publish in the future.

Co-authorship network of co-authors of Jean-Pierre Ayoub

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Pierre Ayoub. A scholar is included among the top collaborators of Jean-Pierre Ayoub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Pierre Ayoub. Jean-Pierre Ayoub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dièras, Véronique, Hyo S. Han, Hans Wildiers, et al.. (2024). Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. European Journal of Cancer. 200. 113580–113580. 7 indexed citations

Arun, Banu, Hyo S. Han, Bella Kaufman, et al.. (2021). Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. European Journal of Cancer. 154. 35–45. 12 indexed citations

Han, Hyo S., Banu Arun, Bella Kaufman, et al.. (2021). Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Annals of Oncology. 33(3). 299–309. 26 indexed citations

Ayoub, Jean-Pierre, et al.. (2020). Prognosis in Young Women less than 40 Years of Age with Brain Metastasis from Breast Cancer. Current Oncology. 27(1). 39–45. 6 indexed citations

Chia, Stephen, Sanjiv K. Gandhi, Anil A. Joy, et al.. (2015). Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer. Current Oncology. 22(1). 33–48. 93 indexed citations

Hirsh, Vera, Denis Soulières, Marie Duclos, et al.. (2007). Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(10). 927–932. 8 indexed citations

Shah, Amil M., et al.. (2005). Surrogate Endpoints in Colorectal Cancer. Current Oncology. 12(4). 136–146. 1 indexed citations

Miles, David, Svetislava J. Vukelja, Vladimir Moiseyenko, et al.. (2004). Survival Benefit with Capecitabine/Docetaxel Versus Docetaxel Alone: Analysis of Therapy in a Randomized Phase III Trial. Clinical Breast Cancer. 5(4). 273–278. 40 indexed citations

Leyland‐Jones, Brian, et al.. (2003). Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. Journal of Clinical Oncology. 21(21). 3965–3971. 212 indexed citations

10.

Leyland‐Jones, Brian, Andrew Arnold, Karen Gelmon, et al.. (2001). Pharmacologic insights into the future of trastuzumab. Annals of Oncology. 12. S43–S47. 16 indexed citations

11.

Ayoub, Jean-Pierre, et al.. (2000). Synchronous appearance of germ cell tumor and papillary carcinoma of the thyroid. American Journal of Otolaryngology. 21(6). 416–420. 2 indexed citations

12.

Ayoub, Jean-Pierre, J. Lynn Palmer, Yang O. Huh, Fernando Cabanillas, & Anas Younes. (1999). Therapeutic and Prognostic Implications of Peripheral Blood Lymphopenia in Patients with Hodgkin's Disease. Leukemia & lymphoma. 34(5-6). 519–527. 31 indexed citations

13.

Ayoub, Jean-Pierre, Kenneth R. Hess, M C Abbruzzese, et al.. (1998). Unknown primary tumors metastatic to liver.. Journal of Clinical Oncology. 16(6). 2105–2112. 61 indexed citations

14.

Ayoub, Jean-Pierre, Andreas H. Sarris, F. B. Hagemeister, et al.. (1997). Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology. 96(2). 328–332. 31 indexed citations

15.

Murray, Nevin, Benny Zee, Joseph L. Pater, et al.. (1997). 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study. Lung Cancer. 18. 61–61. 2 indexed citations

16.

Ayoub, Jean-Pierre, et al.. (1996). Renewable energy activities in rural Argentina — Educational aspects. Renewable Energy. 9(1-4). 1194–1198. 5 indexed citations

17.

Arnold, Andrew, et al.. (1994). Phase II Trial of 13-cis-Retinoic Acid Plus Interferon in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group. JNCI Journal of the National Cancer Institute. 86(4). 306–309. 17 indexed citations

18.

Jolivet, Jacques, K. Bélanger, Louise Yelle, et al.. (1994). The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. European Journal of Cancer. 30(5). 626–628. 3 indexed citations

19.

Ayoub, Jean-Pierre, et al.. (1994). [Chemoprevention of lung cancer].. PubMed. 122(6). 442–5. 8 indexed citations

20.

Ruffiè, Pierre, R. Feld, Salomon Minkin, et al.. (1989). Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.. Journal of Clinical Oncology. 7(8). 1157–1168. 274 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact